Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$4.2M
Filings
51
Firms Hired
2
Active Period
2016–2024
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2024 · third_quarter · Firm: ABIOMED, INC.
Issues related to establishing heart recovery as the standard of care, Support for H.R. Res 1301 Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to health equity and diversity in clinical trials Constituent issue follow-up
Client expense: $160,000 · Firm income: —
Matched citations: HR 1691
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2024 · second_quarter · Firm: ABIOMED, INC.
Issues related to establishing heart recovery as the standard of care, Support for H.R. Res 1301 Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to medical device supply chain and sterilization Issues related to health equity and diversity in clinical trials
Client expense: $160,000 · Firm income: —
Matched citations: HR 1691
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2024 · first_quarter · Firm: ABIOMED, INC.
Issues related to establishing heart recovery as the standard of care Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to medical device supply chain and sterilization Issues related to health equity and diversity in clinical trials Support for R&D expensing deduction for MedTech
Client expense: $160,000 · Firm income: —
Matched citations: HR 1691
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2023 · fourth_quarter · Firm: ABIOMED, INC.
Issues related to the implementation of the FDA Medical Device User Fee Agreement (MDUFA) Issues related to establishing heart recovery as the standard of care Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to medical device supply chain and sterilization Issues related to health equity and diversity in clinical trials Issues related to healthcare cost transparency, HR 5378 and S 3548 Issues related to CMS coverage determinations, HR 5389 and HR 5392
Client expense: $170,000 · Firm income: —
Matched citations: HR 1691
Lower Costs, More Transparency Act
2023 · fourth_quarter · Firm: ABIOMED, INC.
Issues related to the implementation of the FDA Medical Device User Fee Agreement (MDUFA) Issues related to establishing heart recovery as the standard of care Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to medical device supply chain and sterilization Issues related to health equity and diversity in clinical trials Issues related to healthcare cost transparency, HR 5378 and S 3548 Issues related to CMS coverage determinations, HR 5389 and HR 5392
Client expense: $170,000 · Firm income: —
Matched citations: HR 5378
National Coverage Determination Transparency Act
2023 · fourth_quarter · Firm: ABIOMED, INC.
Issues related to the implementation of the FDA Medical Device User Fee Agreement (MDUFA) Issues related to establishing heart recovery as the standard of care Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to medical device supply chain and sterilization Issues related to health equity and diversity in clinical trials Issues related to healthcare cost transparency, HR 5378 and S 3548 Issues related to CMS coverage determinations, HR 5389 and HR 5392
Client expense: $170,000 · Firm income: —
Matched citations: HR 5389
Timely Access to Coverage Decisions Act of 2023
2023 · fourth_quarter · Firm: ABIOMED, INC.
Issues related to the implementation of the FDA Medical Device User Fee Agreement (MDUFA) Issues related to establishing heart recovery as the standard of care Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to medical device supply chain and sterilization Issues related to health equity and diversity in clinical trials Issues related to healthcare cost transparency, HR 5378 and S 3548 Issues related to CMS coverage determinations, HR 5389 and HR 5392
Client expense: $170,000 · Firm income: —
Matched citations: HR 5392
Health Care Prices Revealed and Information to Consumers Explained Transparency Act
2023 · fourth_quarter · Firm: ABIOMED, INC.
Issues related to the implementation of the FDA Medical Device User Fee Agreement (MDUFA) Issues related to establishing heart recovery as the standard of care Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to medical device supply chain and sterilization Issues related to health equity and diversity in clinical trials Issues related to healthcare cost transparency, HR 5378 and S 3548 Issues related to CMS coverage determinations, HR 5389 and HR 5392
Client expense: $170,000 · Firm income: —
Matched citations: S 3548
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2023 · third_quarter · Firm: ABIOMED, INC.
Issues related to the implementation of the FDA Medical Device User Fee Agreement (MDUFA) Issues related to establishing heart recovery as the standard of care Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to IPPS rule making and changes related to external heart assist Issues related to medical device supply chain and sterilization Issues related to healthcare work force development Issues related to health equity and diversity in clinical trials FDA approval pathways for medical technologies Cardiovascular health
Client expense: $160,000 · Firm income: —
Matched citations: HR 1691
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2023 · second_quarter · Firm: ABIOMED, INC.
Issues related to the implementation of the FDA Medical Device User Fee Agreement Issues related to heart recovery Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to the Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization Issues related to medical device supply chain and sterilization Issues related to healthcare work force development
Client expense: $160,000 · Firm income: —
Matched citations: HR 1691
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2023 · first_quarter · Firm: ABIOMED, INC.
Issues related to the implementation of the FDA Medical Device User Fee Agreement Issues related to heart recovery Education on CMS coverage for breakthrough technologies, HR 1691 Issues related to the Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization Issues related to medical device supply chain and sterilization Issues related to healthcare work force development
Client expense: $150,000 · Firm income: —
Matched citations: HR 1691
Protect Medical Innovation Act of 2019
2019 · fourth_quarter · Firm: ABIOMED, INC.
H.R. 2207, S. 692, and bills related to repeal of the medical device excise tax
Client expense: $130,000 · Firm income: —
Matched citations: H.R. 2207
Protect Medical Innovation Act of 2019
2019 · fourth_quarter · Firm: ABIOMED, INC.
H.R. 2207, S. 692, and bills related to repeal of the medical device excise tax
Client expense: $130,000 · Firm income: —
Matched citations: S. 692
Protect Medical Innovation Act of 2019
2019 · third_quarter · Firm: ABIOMED, INC.
H.R. 2207, S. 692, and bills related to repeal of the medical device excise tax
Client expense: $110,000 · Firm income: —
Matched citations: H.R. 2207
Protect Medical Innovation Act of 2019
2019 · third_quarter · Firm: ABIOMED, INC.
H.R. 2207, S. 692, and bills related to repeal of the medical device excise tax
Client expense: $110,000 · Firm income: —
Matched citations: S. 692
Protect Medical Innovation Act of 2019
2019 · second_quarter · Firm: ABIOMED, INC.
H.R. 2207, S. 692, and bills related to repeal of the medical device excise tax
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 2207
Protect Medical Innovation Act of 2019
2019 · second_quarter · Firm: ABIOMED, INC.
H.R. 2207, S. 692, and bills related to repeal of the medical device excise tax
Client expense: $100,000 · Firm income: —
Matched citations: S. 692
Protect Medical Innovation Act of 2019
2019 · first_quarter · Firm: ABIOMED, INC.
H.R. 2207, S. 692, and bills related to repeal of the medical device excise tax
Client expense: $120,000 · Firm income: —
Matched citations: H.R. 2207
Protect Medical Innovation Act of 2019
2019 · first_quarter · Firm: ABIOMED, INC.
H.R. 2207, S. 692, and bills related to repeal of the medical device excise tax
Client expense: $120,000 · Firm income: —
Matched citations: S. 692
Protect Medical Innovation Act of 2018
2018 · fourth_quarter · Firm: ABIOMED, INC.
H.R. 184, S. 108 Medical Device Access and Innovation Protection Act. Bills related to the Medical Device Excise Tax. Issues related to improved awareness of cardiovascular disease and the new field of heart recovery. Issues related to access for heart assist devices.
Client expense: $110,000 · Firm income: —
Matched citations: H.R. 184
Medical Device Access and Innovation Protection Act
2018 · fourth_quarter · Firm: ABIOMED, INC.
H.R. 184, S. 108 Medical Device Access and Innovation Protection Act. Bills related to the Medical Device Excise Tax. Issues related to improved awareness of cardiovascular disease and the new field of heart recovery. Issues related to access for heart assist devices.
Client expense: $110,000 · Firm income: —
Matched citations: S. 108
Protect Medical Innovation Act of 2018
2018 · third_quarter · Firm: ABIOMED, INC.
H.R. 184, S. 108 Medical Device Access and Innovation Protection Act. Bills related to the Medical Device Excise Tax. Issues related to improved awareness of cardiovascular disease and the new field of heart recovery. Issues related to access for heart assist devices.
Client expense: $80,000 · Firm income: —
Matched citations: H.R. 184
Medical Device Access and Innovation Protection Act
2018 · third_quarter · Firm: ABIOMED, INC.
H.R. 184, S. 108 Medical Device Access and Innovation Protection Act. Bills related to the Medical Device Excise Tax. Issues related to improved awareness of cardiovascular disease and the new field of heart recovery. Issues related to access for heart assist devices.
Client expense: $80,000 · Firm income: —
Matched citations: S. 108
Protect Medical Innovation Act of 2018
2018 · second_quarter · Firm: ABIOMED, INC.
H.R. 184, S. 108 Medical Device Access and Innovation Protection Act. Bills related to the Medical Device Excise Tax. Issues related to improved awareness of cardiovascular disease and the new field of heart recovery. Issues related to Ensuring Access to Critical Breakthrough Products Act Issues related to access and CMS reimbursement for heart assist devices.
Client expense: $80,000 · Firm income: —
Matched citations: H.R. 184
Medical Device Access and Innovation Protection Act
2018 · second_quarter · Firm: ABIOMED, INC.
H.R. 184, S. 108 Medical Device Access and Innovation Protection Act. Bills related to the Medical Device Excise Tax. Issues related to improved awareness of cardiovascular disease and the new field of heart recovery. Issues related to Ensuring Access to Critical Breakthrough Products Act Issues related to access and CMS reimbursement for heart assist devices.
Client expense: $80,000 · Firm income: —
Matched citations: S. 108
Source: Senate LDA